Target Conditions

iVeena is targeting the following ophthalmic disease states and has developed solutions to mitigate these diseases:

Post Surgery Cataract Inflammation (IVMED-10 and IVMED-20)

We are all born with a lens inside each eye, which becomes cloudy with time if one lives long enough. The cloudy lens is called a cataract, and without therapy, can cause all vision to become fuzzy. Vision can be restored by surgery to remove cataracts, which is the most common surgery in the US. In 2014, almost 4 million cataract surgeries were done in America and over 20 million worldwide. After surgery, patients typically have to take 3 different drops at 3 different schedules for 3 different periods of time to help the eye heal and protect it from complications. This is difficult and patients often do not take their medications as prescribed, leading to complications even if the surgery went perfectly. iVeena’s lead product, IVMED-10, is intended to facilitate the introduction of drop-free cataract surgery. IVMED-20 treats patients with high risk for Retinal Swelling.

Keratoconus (IVMED-80) Orphan Drug Candidate:

First eye-drop, non-surgical, non-laser treatment for medical crosslinking for keratoconus. Degenerative disorder causing cornea to become conical in shape. The condition may lead to corneal transplant. Estimated prevalence < 50/100,000 (~160,000 in US qualifying as orphan disease). Opportunities in other indications (e.g., reduce risk of ectasia after LASIK)

Prevention of Progressive Myopia (IVMED-85)

Myopia, also known as nearsightedness, causes blurry vision of further away objects while close up objects appear in focus. It is predicted that half the world will suffer from Myopia by the year 2050. The disease disproportionately affects Asian populations (South Eastern, Chinese, Japanese, & Korean) where prevelances have been reported as high as 90% in the younger generations. This rapid rise in Myopia occurrence has been linked to trends of increased viewing of electronic screens and less time being spent outside. When the disease presents in early childhood it often progressively worsens at a rapid rate (>-0.5 Diopters/year). This is attributed to an abnormal lengthening of the eye. IVMED-80 is an eye drop that flattens the cornea, with observable affects as soon as 6 weeks, decreasing the axial length of the eye.